1. Home
  2. LQDA vs PAY Comparison

LQDA vs PAY Comparison

Compare LQDA & PAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

LQDA

Liquidia Corporation

HOLD

Current Price

$68.52

Market Cap

5.5B

Sector

Health Care

ML Signal

HOLD

Logo Paymentus Holdings Inc.

PAY

Paymentus Holdings Inc.

HOLD

Current Price

$36.39

Market Cap

5.1B

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
LQDA
PAY
Founded
2004
2004
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Computer Software: Prepackaged Software
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
5.5B
5.1B
IPO Year
2020
2021

Fundamental Metrics

Financial Performance
Metric
LQDA
PAY
Price
$68.52
$36.39
Analyst Decision
Strong Buy
Buy
Analyst Count
11
8
Target Price
$41.00
$36.29
AVG Volume (30 Days)
1.5M
1.0M
Earning Date
05-08-2026
05-04-2026
Dividend Yield
N/A
N/A
EPS Growth
51.81
48.57
EPS
1.26
0.36
Revenue
$158,320,000.00
$1,196,507,000.00
Revenue This Year
$278.87
$18.60
Revenue Next Year
$57.13
$18.89
P/E Ratio
$54.56
$100.89
Revenue Growth
1031.18
37.25
52 Week Low
$21.15
$20.11
52 Week High
$93.61
$45.31

Technical Indicators

Market Signals
Indicator
LQDA
PAY
Relative Strength Index (RSI) 40.05 49.01
Support Level $30.48 $27.82
Resistance Level $92.35 $36.96
Average True Range (ATR) 3.20 1.71
MACD -0.54 -0.85
Stochastic Oscillator 22.32 23.10

Price Performance

Historical Comparison
LQDA
PAY

About LQDA Liquidia Corporation

Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also conducting studies on L606, an investigational, liposomal formulation of treprostinil.

About PAY Paymentus Holdings Inc.

Paymentus Holdings Inc provides electronic bill presentment and payment services, enterprise customer communication and self-service revenue management to billers through a Software-as-a-Service (SaaS), secure, omni-channel technology platform. The platform integrates with a biller's financial and operational systems to provide secure and flexible processing of payments, including credit cards, debit cards, eChecks, and digital wallets, across multiple channels such as online, mobile, IVR, call centers, chatbots, and voice-based assistants. The company generates the majority of its revenue from payment transaction fees processed through its platform. Geographically, it derives the maximum revenue from the United States.

Share on Social Networks: